Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/28/2025 | $11.00 → $9.00 | Hold → Sell | Deutsche Bank |
| 2/26/2024 | $23.00 | Market Perform | Leerink Partners |
| 2/20/2024 | Hold → Reduce | HSBC Securities | |
| 1/3/2024 | $21.00 | Underweight | Barclays |
| 12/22/2023 | $27.00 | Hold | HSBC Securities |
| 10/23/2023 | $27.00 → $30.00 | Neutral → Overweight | JP Morgan |
| 7/3/2023 | $37.00 → $27.00 | Underweight | Morgan Stanley |
| 6/28/2023 | $46.00 → $34.00 | Buy → Hold | Deutsche Bank |
Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release
Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Super Micro Computer Inc. (NASDAQ:SMCI), will become a component of the Nasdaq-100 Index® (NASDAQ:NDX) and the Nasdaq-100 Equal Weighted™ Index (NASDAQ:NDXE) prior to market open on Monday, July 22, 2024. Super Micro Computer Inc. will replace Walgreens Boots Alliance Inc. (NASDAQ:WBA) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted Index. Walgreens Boots Alliance Inc. will also be removed from the Nasdaq-100 Ex-Tech Sector™ Index (NASDAQ:NDXX), the Nasdaq-100 ESG™ Index (NASDAQ:NDXESG), and the Nasdaq-100 Sustainable ESG Select™ Index (NASDAQ:NDXSES) on the same date. Super Micro Computer Inc
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously
Leerink Partners initiated coverage of Walgreens Boots Alliance with a rating of Market Perform and set a new price target of $23.00
HSBC Securities downgraded Walgreens Boots Alliance from Hold to Reduce
First-of-its-kind program aims to reduce pre-requisite costs, which remain common barriers for pharmacy technicians looking to pursue a PharmD degree. Walgreens, the nation's largest independent community pharmacy provider, has teamed up with Guild, the leading talent development company, to launch PharmStart, a first-of-its-kind, fully funded online education program designed to help eligible team members meet the prerequisite requirements for pharmacy school. The program aims to eliminate barriers to pursuing a PharmD degree, tapping into a new pool of talent while also addressing critical challenges in the pharmacist talent pipeline. This press release features multimedia. View the full
Walgreens is calling on the public to help in the fight against prescription drug abuse by participating in National Prescription Drug Take Back Day on Saturday, April 26th, 2025. Drug take-back days are reserved annually for the safe disposal of unwanted, unused, or expired medications. Walgreens has more than 1,500 kiosks across 46 states and Washington, D.C. These kiosks are a convenient way to ensure medications are not accidentally or intentionally misused. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250421063789/en/Walgreens Encourages Safe Drug Disposal on National Drug Take Back Day Saturday, April 26, 2025 This public
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)
SCHEDULE 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal
Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior
Transaction Highlights Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional
Walgreens Boots Alliance, Inc. (NASDAQ:WBA) today announced that its board of directors is suspending the company's cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company's broader long-term turnaround efforts. This change in capital allocation is aimed at strengthening WBA's balance sheet by reducing debt over time and improving free cash flow, as the company works toward achieving a retail pharmacy-led turnaround underpinned by a sustainable economic model. The company's cash needs over the next several years, including with respect to litigation and debt refinancing,
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)
SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)
4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)